What is the current Supernus Pharmaceuticals market capitalization?
The current market capitalization of Supernus Pharmaceuticals is 1.59 B USD.
Supernus Pharmaceuticals Market capitalization 2024
Supernus Pharmaceuticals Market capitalization
1.59 B USD
Ticker
SUPN
ISIN
US8684591089
WKN
A1JX3U
In 2024, Supernus Pharmaceuticals's market cap stood at 1.59 B USD, a -9.05% increase from the 1.75 B USD market cap in the previous year.
The Supernus Pharmaceuticals Market capitalization history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) | NET INCOME (undefined USD) |
|---|---|---|---|
| 2029e | 907.8 | 57,69 | 322.4 |
| 2028e | 852.41 | 61,44 | 269.13 |
| 2027e | 794.87 | 65,89 | 223.72 |
| 2026e | 707.33 | 74,04 | 157.74 |
| 2025e | 637.1 | 82,21 | 117.56 |
| 2024e | 612.12 | 85,56 | 97.93 |
| 2023 | 607.52 | 86,21 | 1.32 |
| 2022 | 667.2 | 86,93 | 60.7 |
| 2021 | 579.8 | 87,05 | 53.4 |
| 2020 | 520.4 | 89,91 | 127 |
| 2019 | 392.8 | 95,75 | 113.1 |
| 2018 | 408.9 | 96,23 | 111 |
| 2017 | 302.2 | 94,97 | 57.3 |
| 2016 | 215 | 94,42 | 91.2 |
| 2015 | 147.5 | 94,24 | 13.9 |
| 2014 | 92.7 | 93,74 | -10.9 |
| 2013 | 12 | 90,83 | -92.3 |
| 2012 | 1.5 | 100,00 | -47.4 |
| 2011 | 0.8 | 100,00 | 50.4 |
| 2010 | 0.1 | 523742,00 | -41.9 |
| 2009 | 37.9 | 1381,91 | -3 |
| 2008 | 8.9 | 5884,74 | -36.9 |
| 2007 | 4.2 | 12470,05 | -20.7 |
| 2006 | 6.3 | 8313,37 | -8.2 |
Supernus Pharmaceuticals Aktienanalyse
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Supernus Pharmaceuticals's Market Capitalization
Supernus Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Supernus Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Supernus Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Supernus Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Supernus Pharmaceuticals stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Supernus Pharmaceuticals.
How has the market capitalization of Supernus Pharmaceuticals developed in recent years?
The market capitalization of Supernus Pharmaceuticals has increased/decreased by -9.05% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Supernus Pharmaceuticals?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Supernus Pharmaceuticals?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Supernus Pharmaceuticals have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Supernus Pharmaceuticals pay?
Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.
What is the dividend yield of Supernus Pharmaceuticals?
The current dividend yield of Supernus Pharmaceuticals is .
When does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Supernus Pharmaceuticals?
Supernus Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Supernus Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Supernus Pharmaceuticals located?
Supernus Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Supernus Pharmaceuticals from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.
When did Supernus Pharmaceuticals pay the last dividend?
The last dividend was paid out on 7/16/2024.
What was the dividend of Supernus Pharmaceuticals in the year 2023?
In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.
In which currency does Supernus Pharmaceuticals pay out the dividend?
The dividends of Supernus Pharmaceuticals are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Supernus Pharmaceuticals
Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Supernus Pharmaceuticals Revenue
- Supernus Pharmaceuticals Net Income
- Supernus Pharmaceuticals P/E
- Supernus Pharmaceuticals P/S
- Supernus Pharmaceuticals EBIT
- Supernus Pharmaceuticals Dividend
- Supernus Pharmaceuticals Stocks
- Supernus Pharmaceuticals Market capitalization
- Supernus Pharmaceuticals Debt
- Supernus Pharmaceuticals Liabilities
- Supernus Pharmaceuticals Equity
- Supernus Pharmaceuticals AAQS
- Supernus Pharmaceuticals Employees
- Supernus Pharmaceuticals ROE
- Supernus Pharmaceuticals ROA
- Supernus Pharmaceuticals ROCE
